[Cost-benefit of the Schilling test using cobalt-57].

Our purpose in the present publication is to determine the cost-benefit relation of the Schilling test used to measure the intestinal absorption of radioactive vitamin B12. The 60Co-B12 urinary excretion Schilling test was first reported in 1953, and five years later it was being performed at the National Institute of Nutrition (INNSZ) in Mexico City. It was performed in its original version until 1969 and from 1970 to 1980, the direct absorption was measured with a whole-body counter.

The pharmacokinetic characteristics of a hepatobiliary 99mTc-radiopharmaceutical: comparison of the imported and national kits.

In nuclear medicine, the search for the perfect hepatobiliary agent started in 1955 with the rose bengal dye labeled with 131I. With the advent of technetium-99m, many ligands were labeled and Tc-99m-PG and 99mTc-HIDA were among the best suited for this purpose. Both were synthesized at the radiopharmacy laboratory during 1977-1980 and have been used at INNSZ for clinical studies.

Polysomnographic effects of thyroid hormones primary myxedema.

Nine primary myxedematous patients were subjected to all-night polysomnographic recordings under the following conditions: (1) basal or myxedematous state; (2) acute replacement therapy (treatment with thyroid hormones at doses that increased weekly to the maximal replacement dose, Mrd); and (3) chronic replacement therapy (maintenance on the Mrd; euthyroid state). The most striking abnormality found in the sleep pattern during the myxedematous state was observed in both young adult (greater than 20 years old) and adult (greater than 50 years old) patients, consisting of either a complete absence or very low levels of slow wave sleep (SWS). Replacement therapy was accompanied by a restoration of the normal sleep pattern in 3 of the 4 patients that were followed.

Neuroendocrine and electroencephalographic sleep changes due to acute amphetamine ingestion in human beings.

Amphetamine, a clinically used sympathomimetic central-acting drug, was administered in Spansule capsules in a blind schedule to 8 normal obse volunteers in a daily (8 a.m.) single 15 dose for 7 days.